Curacle Co. Ltd.
curacle co.,ltd., a bio-venture business, engages in the research and development of drugs for intractable vascular and metabolic diseases due to aging. The company's products in pipeline include CU06, a next-generation oral therapy, which completed phase 2a clinical trial for the treatment of diabetic macular edema; CU01, which completed Phase 2b clinical trial for Nrf2 activation and inhibition… Read more
Curacle Co. Ltd. (365270) - Total Liabilities
Latest total liabilities as of September 2025: ₩16.67 Billion KRW
Based on the latest financial reports, Curacle Co. Ltd. (365270) has total liabilities worth ₩16.67 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Curacle Co. Ltd. - Total Liabilities Trend (2018–2024)
This chart illustrates how Curacle Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Curacle Co. Ltd. Competitors by Total Liabilities
The table below lists competitors of Curacle Co. Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Boryung Pharm
KO:003850
|
Korea | ₩537.67 Billion |
|
Protara Therapeutics Inc
NASDAQ:TARA
|
USA | $12.35 Million |
|
C4 Therapeutics Inc
NASDAQ:CCCC
|
USA | $102.49 Million |
|
NEXCOM International Co Ltd
TWO:8234
|
Taiwan | NT$2.75 Billion |
|
I-PEX Inc.
OTCGREY:DAIKF
|
USA | $34.10 Billion |
|
Solbar Ningbo Protein Technology Co., Ltd.
SHG:603231
|
China | CN¥210.14 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Curacle Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Curacle Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Curacle Co. Ltd. (2018–2024)
The table below shows the annual total liabilities of Curacle Co. Ltd. from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩29.34 Billion | +5.07% |
| 2023-12-31 | ₩27.92 Billion | +194.29% |
| 2022-12-31 | ₩9.49 Billion | -9.76% |
| 2021-12-31 | ₩10.51 Billion | +76.36% |
| 2020-12-31 | ₩5.96 Billion | -80.32% |
| 2019-12-31 | ₩30.29 Billion | +147.35% |
| 2018-12-31 | ₩12.25 Billion | -- |